It is a modular urinalysis workflow launched by DIRUI, which can meet the realistic needs of clinical laboratories for automated and high-throughput urine testing.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Agilent Technologies reported after the close of the market that its fiscal first quarter revenues rose 5 percent year over year with gains across all end markets.

On February 26, Mindray and the First Affiliated Hospital of Guangxi Medical University held a signing ceremony at Mindray headquarters in Shenzhen and signed a strategic cooperation agreement.

Natera reported after the close of market Tuesday year-over-year revenue gains of approximately 26 percent for the fourth quarter of 2022 and 31 percent for the full year.

Roche announced that it has expanded its partnership with the US Centers for Disease Control and Prevention to improve HIV and tuberculosis prevention, testing, and treatment.

On February 24, China National Medical Device Co., Ltd. and GE Healthcare China signed an agreement in Beijing to establish a medical equipment joint venture in China to meet the growing demand of China's medical and health market.

The $3.95 billion worldwide molecular diagnostic POC testing market is seeing increasing international activity with China becoming a particularly intriguing part of the Asia Pacific region according to The Market and Future Potential for Molecular Point of Care, published by Kalorama Information.

CareDx reported after the close of the market on Monday year-over-year revenue gains of 4 percent for the fourth quarter of 2022 and 9 percent for the full year.

POCT is a clinical test that is performed next to the patient and sampled on-site for immediate analysis. Simplicity and convenience are always the most important features of POCT.

The US Food and Drug Administration said on Friday evening that it has issued an Emergency Use Authorization for Lucira Health's Lucira COVID-19 & Flu test, the first over-the-counter, at-home diagnostic test that can differentiate and detect influenza A and B, as well as SARS-CoV-2.

Chembio Diagnostics has obtained a CLIA waiver from the US Food and Drug Administration for its DPP HIV-Syphilis System, the firm announced on Friday.